January 2024 FDA Recall Rifampin by Amerisource Health Services Llc
D-0285-2024 - Failed Impurities/Degradation Specification.
This Class II drug recall was voluntarily initiated by Amerisource Health Services Llc on January 11, 2024 for the product Rifampin. The FDA reported the reason for recall as failed impurities/degradation specification.. The product was distributed Nationwide and the recall is currently terminated.
Recall Number: D-0285-2024
Failed Impurities/Degradation Specification.
01-11-2024
02-07-2024
1,568 cartons
Recall Profile & Regulatory Data
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
The firm responsible for the recall.
Amerisource Health Services LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
General area of initial distribution.
Nationwide in the USA
09-30-2024
Product Description About Product Description
Full technical description of the product.
Full technical description of the product.
Rifampin Capsules USP, 150 mg, 30 Capsules (3 x 10) unit doses per carton, Rx Only, Distributed by: American Health Packaging, Columbus, Ohio 43217. NDC Carton: 60687-575-21; NDC Unit Dose: 60687-575-11
Batch or Lot Expiration Information
Lot# : 1008111, Exp. Date 01/31/2024
